Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching vs. Maintaining Antidepressants in MDD Early Non-responders
NCT00519012Phase 4Unknown
- Sponsor
- Oizumi Hospital
- Start
- Aug 2007
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sertraline and paroxetine in major depressive disorder (MDD), sponsored by Oizumi Hospital. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 24 weeks. Status: unknown.
02
Drugs
sertralineparoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00519012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00519012.